CN106727508A - A kind of combination drug for treating chronic dysentery - Google Patents
A kind of combination drug for treating chronic dysentery Download PDFInfo
- Publication number
- CN106727508A CN106727508A CN201611253300.6A CN201611253300A CN106727508A CN 106727508 A CN106727508 A CN 106727508A CN 201611253300 A CN201611253300 A CN 201611253300A CN 106727508 A CN106727508 A CN 106727508A
- Authority
- CN
- China
- Prior art keywords
- parts
- combination drug
- chronic dysentery
- treatment
- acevaltralte
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of combination drug for treating chronic dysentery, the combination drug of the treatment chronic dysentery is according to the primary raw material of weight portion：18 30 parts of madder, 5 15 parts of A allocryptopines, 8 12 parts of nutmeg, 5 12 parts of ilicin A, 48 parts of methylophiopogonanone B, 26 parts of triptophenolide, 28 parts of acevaltralte, 7 14 parts of the O B D glucuronic acid methyl esters of Gypsogenin 3,5 18 parts of eupatilin.Medicine of the present invention is strictly selected material composition according to the understanding mechanism of chronic dysentery, so as to reach the purpose of comprehensive rehabilitation, with rapid-action, effect stabilization, carry convenient to take, long-term taking and have no toxic side effect the characteristics of.
Description
Technical field
The present invention relates to a kind of field of medicine preparation, specifically a kind of combination drug for treating chronic dysentery.
Background technology
Dysentery clinical manifestation is stomachache, diarrhoea, tenesmus, apocenosis bloody stool, with symptoms such as systemic toxicity profiles.Baby is to infection
Reaction is not strong, and onset is relatively delayed, and it is in indigestion sample loose stools that stool initially more, and the course of disease is easily delayed.More than 3 years old infant onset urgency, with
Heating, diarrhoea, stomachache are cardinal symptom, can faint from fear, vomit.Will Hayes or good fortune Salmonella the infected's state of an illness are heavier, easily occur
Toxic dysentery, is more common in 3~7 years old children.Artificial feeding infant's constitution is weaker, complication easily occurs.Chronic bacillary dysentery is big
More because acute stages treated is improper, or nutritious bad, rickets, intestinal parasitic disease and the health etc. that is not careful in one's diet usually
Many reasons are caused.Often appear as atypical dysentery symptom, stomachache, diarrhoea, abdominal distension etc..When suffer from cold or take food raw food food
Thing, can cause acute attack, now can suffer from diarrhoea, suffer from abdominal pain and draw pus and blood stool.When it is good when it is bad, although treatment, effect is also good, delay
Do not heal.
The content of the invention
It is an object of the invention to provide a kind of combination drug for treating chronic dysentery, to solve to be carried in above-mentioned background technology
The problem for going out.
To achieve the above object, the present invention provides following technical scheme：
A kind of combination drug for treating chronic dysentery, be according to the primary raw material of weight portion：Madder 18-30 parts, A- it is not hidden
5-15 parts of product alkali, nutmeg 8-12 parts, 5-12 parts of ilicin A, methylophiopogonanone B 4-8 parts, triptophenolide 2-
6 parts, acevaltralte 2-8 parts, 7-14 parts, eupatilin 5-18 parts of Gypsogenin 3-O-B-D- glucuronic acid methyl esters.
As further scheme of the invention：The combination drug of the treatment chronic dysentery, according to the main original of weight portion
Expect be：Madder 22-26 parts, 7-12 parts of A- allocryptopines, nutmeg 9-11 parts, 7-11 parts of ilicin A, methyl tuber of dwarf lilyturf dihydro it is high
4-8 parts of isoflavones B, triptophenolide 2-6 parts, acevaltralte 2-8 parts, Gypsogenin 3-O-B-D- glucuronic acid methyl esters
7-14 parts, eupatilin 6-12 parts.
As further scheme of the invention：The combination drug of the treatment chronic dysentery, according to the main original of weight portion
Expect be：24 parts of madder, 10 parts of A- allocryptopines, 10 parts of nutmeg, 9 parts of ilicin A, methylophiopogonanone B 6
Part, 4 parts of triptophenolide, 5 parts of acevaltralte, 10 parts of Gypsogenin 3-O-B-D- glucuronic acid methyl esters, eupatilin 9
Part.
A kind of preparation method of the combination drug for treating chronic dysentery, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh madder, A- allocryptopines, nutmeg, ilicin A,
It is methylophiopogonanone B, triptophenolide, acevaltralte, Gypsogenin 3-O-B-D- glucuronic acid methyl esters, different
Eupatorin, sieving, machinery adds ultra-pure water after mixing, place in pharmacy mixer, mixes 4-8min, controls RSD≤5%,
Compressing tablet and low temperature drying after mixing, at 4-8 DEG C, packaging obtains final product the combination drug for the treatment of chronic dysentery to temperature control.
As further scheme of the invention：Mix 6min in specific steps.
Compared with prior art, the beneficial effects of the invention are as follows：
Medicine of the present invention is strictly selected material composition according to the understanding mechanism of chronic dysentery, so as to reach comprehensive health
Multiple purpose, with rapid-action, effect stabilization, carry convenient to take, long-term taking and have no toxic side effect the characteristics of.
Specific embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the invention, rather than whole embodiments.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
Embodiment 1
A kind of combination drug for treating chronic dysentery, be according to the primary raw material of weight portion：18 parts of madder, A- allocryptopines
5 parts, 8 parts of nutmeg, 5 parts of ilicin A, 4 parts of methylophiopogonanone B, 2 parts of triptophenolide, 2 parts of acevaltralte,
7 parts of Gypsogenin 3-O-B-D- glucuronic acid methyl esters, 5 parts of eupatilin.
A kind of preparation method of the combination drug for treating chronic dysentery, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh madder, A- allocryptopines, nutmeg, ilicin A,
It is methylophiopogonanone B, triptophenolide, acevaltralte, Gypsogenin 3-O-B-D- glucuronic acid methyl esters, different
Eupatorin, sieving, machinery adds ultra-pure water after mixing, place in pharmacy mixer, mixes 4min, controls RSD≤5%, mixes
Compressing tablet and low temperature drying after conjunction, at 4 DEG C, packaging obtains final product the combination drug for the treatment of chronic dysentery to temperature control.
Embodiment 2
A kind of combination drug for treating chronic dysentery, be according to the primary raw material of weight portion：22 parts of madder, A- allocryptopines
7 parts, 9 parts of nutmeg, 7 parts of ilicin A, 4 parts of methylophiopogonanone B, 2 parts of triptophenolide, 2 parts of acevaltralte,
7 parts of Gypsogenin 3-O-B-D- glucuronic acid methyl esters, 6 parts of eupatilin.
A kind of preparation method of the combination drug for treating chronic dysentery, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh madder, A- allocryptopines, nutmeg, ilicin A,
It is methylophiopogonanone B, triptophenolide, acevaltralte, Gypsogenin 3-O-B-D- glucuronic acid methyl esters, different
Eupatorin, sieving, machinery adds ultra-pure water after mixing, place in pharmacy mixer, mixes 4min, controls RSD≤5%, mixes
Compressing tablet and low temperature drying after conjunction, at 4 DEG C, packaging obtains final product the combination drug for the treatment of chronic dysentery to temperature control.
Embodiment 3
A kind of combination drug for treating chronic dysentery, be according to the primary raw material of weight portion：24 parts of madder, A- allocryptopines
10 parts, 10 parts of nutmeg, 9 parts of ilicin A, 6 parts of methylophiopogonanone B, 4 parts of triptophenolide, acevaltralte 5
Part, 10 parts of Gypsogenin 3-O-B-D- glucuronic acid methyl esters, 9 parts of eupatilin.
A kind of preparation method of the combination drug for treating chronic dysentery, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh madder, A- allocryptopines, nutmeg, ilicin A,
It is methylophiopogonanone B, triptophenolide, acevaltralte, Gypsogenin 3-O-B-D- glucuronic acid methyl esters, different
Eupatorin, sieving, machinery adds ultra-pure water after mixing, place in pharmacy mixer, mixes 6min, controls RSD≤5%, mixes
Compressing tablet and low temperature drying after conjunction, at 6 DEG C, packaging obtains final product the combination drug for the treatment of chronic dysentery to temperature control.
Embodiment 4
A kind of combination drug for treating chronic dysentery, be according to the primary raw material of weight portion：26 parts of madder, A- allocryptopines
12 parts, 11 parts of nutmeg, 11 parts of ilicin A, 8 parts of methylophiopogonanone B, 6 parts of triptophenolide, acevaltralte 8
Part, 14 parts of Gypsogenin 3-O-B-D- glucuronic acid methyl esters, 12 parts of eupatilin.
A kind of preparation method of the combination drug for treating chronic dysentery, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh madder, A- allocryptopines, nutmeg, ilicin A,
It is methylophiopogonanone B, triptophenolide, acevaltralte, Gypsogenin 3-O-B-D- glucuronic acid methyl esters, different
Eupatorin, sieving, machinery adds ultra-pure water after mixing, place in pharmacy mixer, mixes 8min, controls RSD≤5%, mixes
Compressing tablet and low temperature drying after conjunction, at 8 DEG C, packaging obtains final product the combination drug for the treatment of chronic dysentery to temperature control.
Embodiment 5
A kind of combination drug for treating chronic dysentery, be according to the primary raw material of weight portion：30 parts of madder, A- allocryptopines
15 parts, 12 parts of nutmeg, 12 parts of ilicin A, 8 parts of methylophiopogonanone B, 6 parts of triptophenolide, acevaltralte 8
Part, 14 parts of Gypsogenin 3-O-B-D- glucuronic acid methyl esters, 18 parts of eupatilin.
A kind of preparation method of the combination drug for treating chronic dysentery, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh madder, A- allocryptopines, nutmeg, ilicin A,
It is methylophiopogonanone B, triptophenolide, acevaltralte, Gypsogenin 3-O-B-D- glucuronic acid methyl esters, different
Eupatorin, sieving, machinery adds ultra-pure water after mixing, place in pharmacy mixer, mixes 8min, controls RSD≤5%, mixes
Compressing tablet and low temperature drying after conjunction, at 8 DEG C, packaging obtains final product the combination drug for the treatment of chronic dysentery to temperature control.
Pharmacology test
1st, chronic toxicity test
It is experiment with combination drug obtained in the embodiment of the present invention 3, using gastric infusion mode, successive administration 3 in 24h
It is secondary, per minor tick 6h, 500mg/kg doses are administered every time, daily accumulation medicine total amount reaches 1500mg medicines/kg, faces equivalent to people
100 times of bed consumption.After administration in 7d, mouse activity, feed, excretion are normal, well-grown, hair color light, its average body
Weight increases with the extension of experimental period.Every mouse of post mortem at 8d, visually observe the heart, liver, spleen, lung, kidney, brain,
Thymus gland, stomach, intestines etc. do not find color and paramophia, fail to measure median lethal dose (LD50).Result shows：The present invention is multiple
Composite medicine is without chronic toxicity.
2nd, long term toxicity test
It is experiment with combination drug obtained in the embodiment of the present invention 3, using gastric infusion mode, by combination drug of the present invention
Be divided into low dosage, middle dosage, three groups of high dose, the drug dose of each group is respectively 150,300,450mg medicines/kg/d, quite
10,20,30 times in clinical dosage.After gastric infusion 24 weeks, medicine of the present invention to the general status of animal, hematological indices,
Blood parameters without obvious influence, Systematic anatomy, organ coefficient and histopathological examination also no abnormal pathology
Change.It is discontinued 2 weeks and also has no substantially change.Result shows：Combination drug of the present invention does not find substantially in long term toxicity test
Toxic reaction and delayed toxicity react.It can be seen that, combination drug non-toxic reaction of the present invention, long-term prescription is safe and reliable.
3rd, clinical test
In April, 2015, in Nanjing, 312 patients screened in hospital in May, 2015, and all patients meet chronic dysentery
Illness.Wherein male 169, women 143, minimal ages 2 years old, max age 72 years old, average age 37.6 years old.All patients
The combination drug of the preparation of the embodiment of the present invention 3 is taken, instructions of taking is：Daily 15mg/kg (patient between 2-12 Sui halves),
2 days courses for the treatment of, treat two courses for the treatment of altogether.
Curative effect situation criterion：Cure：Sign improves completely, and rush down dysentery stops, and diet is normal, in high spirits.It is effective：Body
Levy and significantly improve, rush down dysentery stops substantially, diet is normal, and spirit can.Effectively：Sign improves, and rush down dysentery is reduced, and diet and spirit change
It is kind.It is invalid：Before symptom is as treated.
Therapeutic effect：312 patients, cure 225, effective 49, effective 20, invalid 18, total effective rate
94.2%.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of without departing substantially from spirit or essential attributes of the invention, the present invention can be in other specific forms realized.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit requires to be limited rather than described above, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Moreover, it will be appreciated that although the present specification is described in terms of embodiments, not each implementation method is only wrapped
Containing an independent technical scheme, this narrating mode of specification is only that for clarity, those skilled in the art should
Specification an as entirety, the technical scheme in each embodiment can also be formed into those skilled in the art through appropriately combined
May be appreciated other embodiment.
Claims (5)
1. a kind of combination drug for treating chronic dysentery, it is characterised in that the primary raw material according to weight portion is：Madder 18-30
Part, 5-15 parts of A- allocryptopines, nutmeg 8-12 parts, 5-12 parts of ilicin A, methylophiopogonanone B 4-8 parts,
Triptophenolide 2-6 parts, acevaltralte 2-8 parts, 7-14 parts of Gypsogenin 3-O-B-D- glucuronic acid methyl esters, different Herba Lycopi it is yellow
It is plain 5-18 parts.
2. it is according to claim 1 treatment chronic dysentery combination drug, it is characterised in that the treatment chronic dysentery
Combination drug, be according to the primary raw material of weight portion：Madder 22-26 parts, 7-12 parts of A- allocryptopines, nutmeg 9-11 parts, winter
Blue or green 7-11 parts of element A, methylophiopogonanone B 4-8 parts, triptophenolide 2-6 parts, acevaltralte 2-8 parts, gypsoside
7-14 parts, eupatilin 6-12 parts of aglycon 3-O-B-D- glucuronic acid methyl esters.
3. it is according to claim 1 and 2 treatment chronic dysentery combination drug, it is characterised in that the chronic dysentery for the treatment of
The combination drug of disease, be according to the primary raw material of weight portion：24 parts of madder, 10 parts of A- allocryptopines, 10 parts of nutmeg, ilicin
9 parts of A, 6 parts of methylophiopogonanone B, 4 parts of triptophenolide, 5 parts of acevaltralte, Gypsogenin 3-O-B-D-
10 parts of glucuronic acid methyl ester, 9 parts of eupatilin.
4. the preparation method of the combination drug of a kind for the treatment of chronic dysentery as described in claim 1-3 is any, it is characterised in that
Concretely comprise the following steps：
First, in pharmaceutical grade clean area, madder, A- allocryptopines, nutmeg, ilicin A, methyl are weighed by above-mentioned metering ratio
Tuber of dwarf lilyturf Homoisoflavonoids B, triptophenolide, acevaltralte, Gypsogenin 3-O-B-D- glucuronic acid methyl esters, different Herba Lycopi
Flavine, sieving, machinery adds ultra-pure water after mixing, place in pharmacy mixer, mixes 4-8min, controls RSD≤5%, mixing
Compressing tablet and low temperature drying afterwards, at 4-8 DEG C, packaging obtains final product the combination drug for the treatment of chronic dysentery to temperature control.
5. it is according to claim 4 treatment chronic dysentery combination drug preparation method, it is characterised in that specific steps
Middle mixing 6min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611253300.6A CN106727508A (en) | 2016-12-30 | 2016-12-30 | A kind of combination drug for treating chronic dysentery |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611253300.6A CN106727508A (en) | 2016-12-30 | 2016-12-30 | A kind of combination drug for treating chronic dysentery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106727508A true CN106727508A (en) | 2017-05-31 |
Family
ID=58953112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611253300.6A Pending CN106727508A (en) | 2016-12-30 | 2016-12-30 | A kind of combination drug for treating chronic dysentery |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106727508A (en) |
-
2016
- 2016-12-30 CN CN201611253300.6A patent/CN106727508A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106727508A (en) | A kind of combination drug for treating chronic dysentery | |
| CN106728145A (en) | It is a kind of to treat Chinese and western medicinal composition of acute diarrhea and preparation method thereof | |
| CN106511440A (en) | Compound Chinese and Western medicine composition for treating chronic dysentery and preparation method thereof | |
| CN105056063A (en) | Traditional Chinese medicine composition | |
| CN102552743A (en) | Medicinal composition for treating diabetes and preparation method thereof | |
| CN106581025A (en) | Composite western medicine for treating chronic dysentery | |
| CN106822133A (en) | A kind of Western medicine compound for treating acute diarrhea | |
| CN106727642A (en) | A kind of children's antipyretic | |
| CN106668600A (en) | Composite preparation for treating chronic glomerulitis | |
| CN106822239A (en) | It is a kind of to treat Chinese and western medicinal composition of the infection of the upper respiratory tract and preparation method thereof | |
| CN102895562B (en) | Child spleen invigorating powder | |
| CN106581024A (en) | Western medicine composition for treating hyperlipidemia | |
| CN106727643A (en) | A kind of Western medicine for treating bacterial pneumonia | |
| CN104815308A (en) | Traditional Chinese medicine formula for treating cardiovascular and cerebrovascular diseases | |
| CN106581031A (en) | Compound Western medicine for treating pertussis | |
| CN106620642A (en) | Western medicine composition for treating hyperglycemia | |
| CN106727907A (en) | A kind of Chinese and Western medicine combination for treating viral pneumonia and preparation method thereof | |
| CN106727591A (en) | A kind of pharmaceutical composition for treating Streptococcus suis | |
| CN106728042A (en) | A kind of combination drug for treating bacillary dysentery | |
| CN106620318B (en) | Traditional Chinese medicine composition for treating chronic nephritis | |
| CN101116703A (en) | Medicinal food for treating tapeworm disease | |
| CN106727628A (en) | A kind of Western medicine compound for treating chronic diarrhea | |
| CN104027743B (en) | It is a kind of to treat Chinese medicine composition of hyperlipidemia and preparation method thereof | |
| CN106692294A (en) | Compound Chinese-Western combination for treating pertussis and preparation method thereof | |
| CN106727615A (en) | A kind of Western medicine compound for treating the infection of the upper respiratory tract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170531 |
|
| WD01 | Invention patent application deemed withdrawn after publication |